Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
== Cultivation == Angelica is hardy to 5 °C (41 °F) and can be cultivated at elevations of 1,500 to 3,000 metres (5,000–10,000 ft). Seedlings need to be kept out of direct sunlight, but the mature plant can withstand it. Angelica requires deep moist fertile soil and is perennial if prevented from going to seed.
== Modern therapeutic research == Tetrodotoxin has been investigated as a possible treatment for cancer-associated pain. Early clinical trials demonstrate significant pain relief in some patients. It has also been studied in relation to migraine headaches. Mutations in one particular TTX-sensitive Na+ channel are associated with some migraine headaches, although it is unclear as to whether this has any therapeutic relevance for most people with migraine. Tetrodotoxin has been used clinically to relieve negative affects associated with heroin withdrawal.
=== 1 July === The SAF intercepted RSF drones in Merowe and Al-Dabbah. The RSF and the SPLM-N (al-Hilu) announced the creation in Nyala of a governing alliance headed by Hemedti, with SPLM-N leader Abdelaziz al-Hilu as his deputy.
Wound bed preparation (WBP) is a systematic approach to wound management by identifying and removing barriers to healing. The concept was originally developed in plastic surgery. It includes wound assessment, debridement, moisture balance, bacterial balance, and wound cleaning.
Although many of the largest restaurant chains in Canada are US-based (such as McDonald's and Yum! Brands among others), some Canadian-based (owned and operated from Canada) restaurant chains are growing and have expanded into other markets, especially into the US.
Sources: en.wikipedia.org
In September 1936, Fry's released an aerated Crunchie bar made entirely of chocolate. They justified this move as not breaching the patent, saying it was not a block but a bar. As Aero sales began to dip, Rowntree's brought out variants, selling the first aerated chocolates with fruit and nut inclusions. After Fry's launched a second aerated chocolate in August 1937 called Ripple, Rowntree's had to decide whether they wanted to try to enforce their patent. By this time, Nestlé and Fry's had joined Cadbury in having expressed a willingness to challenge the patent in the courts despite it being officially approved by the patent office. On legal advice that there was a 50% likelihood of success in a court challenge, and the threat of court proceedings causing bad publicity, Rowntree's entered negotiations with other chocolate makers to discuss licensing aerated chocolate. Rival companies were dominant in the proceedings dialogues, and Rowntree's ultimately agreed to licence aerated chocolate from June 1938 under the conditions that chocolate makers pay a sum with the release of new aerated chocolate lines and a 0.5% royalty on sales. After this agreement was put in place, Cadbury only released aerated chocolate products in overseas dominions where Aero was not established. Nestlé-produced aerated chocolates included a chocolate called Bubblo, made in the UK for export to New Zealand under a New Zealand patent. Aerated chocolate was already being sold in some overseas markets, by 1936 for instance, Aero was being successfully exported to Australia.
After the Second World War, researchers began conducting large-scale surveys and proposing broad social indicators to track well-being within nations and in cross-national comparisons. Based on their results, Richard Easterlin (1926–2024) formulated the Easterlin paradox—the observation that richer individuals in a nation report higher happiness than poorer ones, although the average happiness of the population does not increase as the nation's average income rises. Various models of well-being were proposed in the second half of the 20th century and the beginning of the 21st century, including Ed Diener's (1946–2021) tripartite model of subjective well-being, Carol Ryff's (born 1950) six-factor model of psychological well-being, and Martin Seligman's (born 1942) PERMA model. Derek Parfit (1942–2017) analyzed traditional theories of well-being and introduced the influential distinction between hedonism, desire theories, and objective list theories. Another key development was the emergence of positive psychology in the late 1990s, focusing on human flourishing and optimal functioning in contrast to the traditional emphasis of psychological research on illness and dysfunction. The 20th and 21st centuries also saw growing interest in the relation between well-being, economy, and public policy, as governments and international organizations began integrating research on well-being into political decision-making.
The low budget of the project proved to be a significant challenge, as well as the unique challenges of working with child actors. The producers wanted the style of the series to reflect trends begun in other popular and innovative TV shows such as Sesame Street and Laugh-In. Puppetry and animation were frequently used. Sometimes one or two of the kids would conduct "man-on-the-street" interviews, asking ordinary citizens about nutrition-related topics. All of the music, including the theme song and the various songs sung by the kids during an episode (many times in musical "romps" reminiscent of the ones seen on The Monkees TV series), were composed and arranged by Washington, DC musician and recording engineer Paul Brier, and performed by a rock combo credited on screen as "The Eye". Mulligan Stew premiered on October 4, 1972, during the National 4-H Week at the National 4-H Center in Washington, DC. The program was considered a success, especially by previous standards for television outreach sponsored by 4-H. The series had a moderate impact on kids making better choices in what they ate, and provided 4-H with a sizable marketing, promotional and public relations boost. Thanks in part to the popularity of Mulligan Stew, 4-H membership was boosted to an all-time high in 1974, and the series continued to air in reruns on public television until 1981.
In 1982, Ice-T met producer Willie Strong from Saturn Records. In 1983, Strong recorded Ice-T's first single, "Cold Wind Madness", also known as "The Coldest Rap", an electro hip-hop record that became an underground success, becoming popular even though radio stations did not play it due to the song's explicit lyrics about taking a woman to the Snooty Fox motel in Los Angeles. That same year, Ice-T meets Alex Jordanov to set up one of the first hip-hop clubs in Los Angeles, The Radio, where he also meets DJ Chris "The Glove" Taylor. He released "Body Rock", another electro hip-hop single that found popularity in clubs. In 1984, Ice-T was a featured rapper on "Reckless", a single by DJ Chris "The Glove" Taylor and (co-producer) David Storrs that gained widespread popularity as a featured track via the motion picture Breakin' and its soundtrack album. This song was almost immediately followed up with a sequel entitled "Reckless Rivalry (Combat)", which was featured in the Breakin' sequel, Breakin' 2: Electric Boogaloo, however, it was never featured on the soundtrack album and was only released as a single on Taxidermi Records. In 1985, he appeared in the film Rappin' by performing two verses of his track "Killers", which was his first political rap. Ice later recorded the songs "Ya Don't Quit" and "Dog'n the Wax (Ya Don't Quit-Part II)" with Unknown DJ, who provided a Run-DMC–like sound for the songs. Ice-T received further inspiration as an artist from Schoolly D's gangsta rap single "P.S.K. What Does It Mean?", which he heard in a club.
Sources: en.wikipedia.org
=== Steroid structure === Hodgkin was particularly noted for discovering three-dimensional biomolecular structures. In 1945, working with C.H. (Harry) Carlisle, she published the first such structure of a steroid, cholesteryl iodide (having worked with cholesteryls since the days of her doctoral studies).
The first aircraft carrying troopers from the 2–325th touched down at Point Salines 17 hours after H-Hour notification. In March 1988, a brigade task force made up of two battalions from the 504th Infantry and 3d Battalion (Airborne), 505th Infantry, conducted a parachute insertion and air/land operation into Honduras as part of Operation Golden Pheasant. The deployment was billed as a joint training exercise, but the paratroopers were ready to fight. The deployment caused the Sandinistas to withdraw to Nicaragua. Operation Golden Pheasant prepared the paratroopers for future combat in an increasingly unstable world.
One employee stated that "he had been told by a close friend of one of the MIC operators that water had entered through a tube that had been connected to the tank." This had been allegedly discovered by the other MIC operators who then tried to open and close valves to prevent the release. The Little report argues that this evidence demonstrates that the following chronology took place:
Memorials to the attacks include the National September 11 Memorial & Museum in New York City; the Pentagon Memorial in Arlington County, Virginia; and the Flight 93 National Memorial at the Pennsylvania crash site.
== History == Electron-capture dissociation was developed by Roman Zubarev and Neil Kelleher while in Fred McLafferty's lab at Cornell University. Irradiation of melittin 4+ ions and ubiquitin 10+ ions (trapped in FT-MS cell) by laser pulses not only resulted in peculiar c', z fragmentation but also charge reduction. It was suggested that if FT cell is modified to trap cations and electrons simultaneously, secondary electrons emitted by UV photons increases the charge reduction effect and c′, z• fragmentation. Replacing UV laser with EI source led to the development of this new technique.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.